Research programme: degenerative disease therapeutics - 4SC Discovery/CRELUX/Helmholtz Zentrum Munchen

Drug Profile

Research programme: degenerative disease therapeutics - 4SC Discovery/CRELUX/Helmholtz Zentrum Munchen

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator 4SC Discovery; CRELUX; Helmholtz Zentrum Munchen
  • Developer 4SC Discovery; CRELUX
  • Class
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Tissue degeneration

Most Recent Events

  • 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
  • 13 Jan 2015 Preclinical trials in Tissue degeneration in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top